MK-677 vs Tesamorelin
How they differ
- FDA status. MK-677: No FDA approval reported; on FDA’s compounding safety-risk list (category 2).1,2 Tesamorelin: FDA-approved as Egrifta for HIV-associated abdominal fat.3,4
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | MK-677 | Tesamorelin |
|---|---|---|
| What it is | Not a peptide: a small molecule often looked up alongside peptides5,6 A synthetic small-molecule growth hormone secretagogue, recorded by FDA’s substance registry as ibutamoren mesylate and also called MK-677 and MK-0677.5,6 | A growth hormone-releasing factor (GHRF) analogue. The label states that it binds to and stimulates human GRF receptors with potency similar to the natural hormone.3 |
| FDA status | Not FDA-approved No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1,2 No FDA approval is reported in the sources reviewed here. FDA lists ibutamoren mesylate in category 2 of both of its interim compounding policies, for substances that may present significant safety risks, and its advisory committee voted 13 to 1 in 2024 against adding it to the compounding list.1,2 | FDA-approved FDA-approved as Egrifta for HIV-associated abdominal fat3,4 FDA-approved. Drugs@FDA lists Egrifta (first approved November 10, 2010), and the label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. The cited label has no boxed warning.3,4 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. MK-677 is not among them.7,8 | Not among the six peptides the policy lists.7 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.1 | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 11 ClinicalTrials.gov records and 21 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 4Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Ibutamoren mesylate (MK-677) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 6The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo (1998) · PMID 9535057 ↗
Journal of Neuroendocrinology · Official source · Source checked November 16, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 9Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial (2008) · PMID 19015485 ↗
Neurology · Official source · Source checked November 16, 2026
- 10MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study (2011) · PMID 21067829 ↗
Archives of Gerontology and Geriatrics · Official source · Source checked November 16, 2026